Healthcare Industry News: Mylan
News Release - September 16, 2008
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)PITTSBURGH, Sept. 16 (HSMN NewsFeed) -- Mylan Inc. (NYSE: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone Tablets USP, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.
Risperidone Tablets, used to treat schizophrenia and bipolar disorder, are the generic version of Janssen's Risperdal® Tablets. This product had annual U.S. sales of approximately $2.67 billion for the 12 months ending June 30, 2008, for the noted strengths, according to IMS Health.
Mylan will ship the product shortly. Currently, the company has 109 ANDAs pending FDA approval, 22 of which are potential first-to-file opportunities.
Mylan Inc., with a presence in more than 120 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
Statement from Mylan's Board of Directors Regarding Retirement of CEO and Board Member Heather Bresch in Conjunction with the Combination of Mylan and Upjohn, a Division of Pfizer